SigFact

BeiGene (百济神州)

Global biotech company triple-listed on NASDAQ, HKEX, and STAR Market, known for Brukinsa, a best-in-class BTK inhibitor.

Beijing, ChinaAPACAdvantage marketLatest Feb 26, 2026
Add to WatchlistWebsite
Monitoring Status
Signals (30d)
1
Most active type
Financial Results
Primary channel
—
Primary theme
Brukinsa
Latest update
Feb 26, 2026
vs. prior 30 days
Rising

Signal history

1 total
Financial ResultsOfficial sourceFeb 26, 2026

BeOne Medicines reports Q4 revenue of $1.2B (+15% YoY) and FY2025 revenue of $4.5B (+12% YoY), driven by BRUKINSA sales.

BeOne Medicines Reports Q4 and FY 2025 Financial Results

BeOne Medicines announced its fourth quarter and full year 2025 financial results on February 26, 2026. The company highlighted the global success of its product BRUKINSA and its leadership in foundational oncology. The report provides an overview of the company's financial performance and strategic achievements during the period.

Key Changes (30d)

Financial ResultsMar 18Verified

BeOne Medicines reports Q4 revenue of $1.2B (+15% YoY) and FY2025 revenue of $4.5B (+12% YoY), driven by BRUKINSA sales.

BeOne Medicines Reports Q4 and FY 2025 Financial Results

Source Language Distribution

Language distribution will appear as more signals are collected from diverse sources.

Strategic themes and signal pattern

Strategic Themes

BrukinsaOncology pipelineGlobal clinical trialsBTK inhibitorsImmuno-oncology

Recent Signal Pattern

Most frequent signal typeFinancial Results
Activity Trend (30d)
Rising
0
1
Prev 30dLast 30d
Sources tracked2
Total signals tracked1

Why this company matters

BeiGene's Brukinsa is the most commercially successful drug ever developed by a Chinese biotech company, proving that Chinese-originated drugs can compete globally against established pharma.

  • Key domain relevance: Brukinsa, Oncology pipeline, Global clinical trials
  • Active monitoring with 1 signals in the last 30 days across 2 tracked sources.

Channel Context

Channel context will be available once this company is assigned to a primary channel.

Market Context

Beijing, China

This company operates in one of SigFact's strongest advantage markets, where official updates often surface first in local language.

See recent signals in this market

Continue monitoring BeiGene (百济神州)

Follow this company, add it to your watchlist, or explore its signal stream to stay informed.

Add to Watchlist
Explore More Channels
All Channels
AI & Frontier Intelligence222 signalsFintech & Digital Finance86 signalsHealthtech & Biotech35 signalsMobility, EV & Autonomous Systems101 signals